What is the common formulation of buprenorphine that includes naloxone intended to prevent?

Buprenorphine is a partial opioid agonist often used in the treatment of opioid use disorder. When combined with naloxone, such a formulation is specifically designed to deter misuse, particularly through injection. Naloxone is an opioid antagonist that precipitates withdrawal symptoms when injected in individuals who are opioid-dependent. This means that when someone attempts to misuse buprenorphine-naloxone by injecting it, naloxone activates and blocks the effects of the opioid, eliminating the euphoric experience sought by users. This combination thus significantly lowers the potential for misuse and abuse.

The other options do not accurately reflect the primary purpose of the buprenorphine-naloxone formulation. While it can manage withdrawal symptoms effectively if taken orally, that is not the concern addressed by including naloxone. The formulation does not specifically target overdose risks from alcohol since that is not the primary focus of its design; instead, it aims to prevent opioid misuse. Moreover, while tolerance development is a relevant topic in opioid therapy, the combination of buprenorphine with naloxone is not aimed directly at preventing tolerance.